Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 ...

Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology ...

In recent trading, shares of Ionis Pharmaceuticals Inc (NASD: IONS) have crossed above the average analyst 12-month target price of $29.29, changing hands for $38.01/share.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $59.00. Yaron Werber’s rating is based ...

Ionis Pharmaceuticals IONS has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

May 16 (Reuters) - Biogen (BIIB.O), opens new tab and Ionis Pharmaceuticals (IONS.O), opens new tab said on Thursday they will terminate the development of their experimental treatment for ...

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $68.00. Jason Gerberry has given his ...